Abstract: Methods and materials for identifying and treating mammals (e.g., humans) having multiple myeloma (MM) are provided herein. For example, this document provides methods and materials that can be used to identify and treat mammals having advanced stage MM, and/or having MVI that is resistant to treatment with immunomodulatory drugs (IMiDs) and/or proteasome inhibitors (PIs).

Abstract: A system for collecting, generating, and transmitting Gigawatt scale energy is provided. The system comprises a geographically dispersed network comprising a plurality of nodes, each node comprising: a water source; renewable energy sources comprising: a wind turbine string of a plurality of wind turbines; and a solar photovoltaic string; a nodal substation in electrical communication with the renewable energy sources. The nodal substation comprises: at least one electrolyser in electrical communication with the renewable energy sources, the at least one electrolyser configured to convert water from the water source into hydrogen, or hydrogen compound, with electricity from the renewable energy sources; a compressor to compress hydrogen, or hydrogen compound, from the at least one electrolyser into a pipeline fluidly connecting each node.

Abstract: Provided are systems and methods for tactile sensing of a target tissue region of a patient in need thereof.

Abstract: Tactile sensing devices, systems, and methods to image a target tissue location are disclosed. When force is applied to the tactile sensing device, voltage data is detected and visualized on a screen, indicating the target tissue location.

Abstract: Methods, apparatus, and system to measure and control respiration of a perishable commodity in a vacuum chamber, including for purposes of extending a shelf life of a perishable commodity therein, including.

Abstract: Tactile sensing devices, systems, and methods to image a target tissue location are disclosed. When force is applied onto a tissue surface using the tactile sensing device, sensors of a sensor array output voltage signals to a computing device and display screen operatively connected to the sensor array. The sensor array relays its output voltage signals to the computing device, the computing device processes the output voltage signals, and an image of the output voltage signals is visualized on the display screen to help identify a target tissue insertion site.

Abstract: Tactile sensing devices, systems, and methods to image a target tissue location are disclosed. When force is applied to the tactile sensing device, voltage data is detected and visualized on a screen, indicating the target tissue location.

Abstract: Tactile sensing devices, systems, and methods to image a target tissue location are disclosed. When force is applied to the tactile sensing device, voltage data is detected and visualized on a screen, indicating the target tissue location.

Abstract: Tactile sensing devices, systems, and methods to image a target tissue location are disclosed. When force is applied to the tactile sensing device, voltage data is detected and visualized on a screen, indicating the target tissue location.

Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Abstract: This document provides methods and materials related to assessing responsiveness to lenalidomide, thalidomide, and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example, methods and materials for using CRBN levels to determine whether or not cancer cells (e.g., multiple myeloma cells) are susceptible to lenalidomide, thalidomide, and/or other IMiDs are provided.

Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.

Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.

Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.

Abstract: This document provides methods and materials related to assessing responsiveness to lenalidomide, thalidomide, and/or other IMiDs (structural and functional analogues of thalidomide that represent a promising new class of immunomodulators). For example, methods and materials for using CRBN levels to determine whether or not cancer cells (e.g., multiple myeloma cells) are susceptible to lenalidomide, thalidomide, and/or other IMiDs are provided.

Abstract: This document relates to methods and materials for treating multiple myeloma. For example, methods and materials for using albumin-bound paclitaxel composition (e.g., Abraxane®, a paclitaxel albumin-stabilized nanoparticle formulation) to treat multiple myeloma are provided.

Abstract: This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.